DTRA Commits Additional Funds to MeMed's Innovative Bacterial Versus Viral Test and Point-of-Care Platform

Haifa, Israel (ots/PRNewswire) -

MeMed's contract with DTRA is expanded to include key
verification milestones

MeMed today announced DTRA's expanded commitment to their
point-of-care immunoassay platform and ground breaking bacterial
versus viral host-response test.

(Logo: http://mma.prnewswire.com/media/451805/MeMed_Ltd_Logo.jpg )

Dr. Eran Eden, MeMed's co-founder and CEO said: "DTRA's exercise
of an expanded contract further supports our multi-year international
effort to develop a unique platform that can measure multiple
proteins with laboratory precision at the point-of-care, and our
host-response test for distinguishing between bacterial and viral
infection in minutes. The test has the potential to address a daily
clinical dilemma that is a fundamental driver of antibiotic misuse -
the difficulty in distinguishing between bacterial and viral
infections."

"We greatly value our relationship with the Department of Defense,
which reflects an alignment of interests to develop diagnostic
technologies that help improve public health," said Dr. Tanya
Gottlieb, MeMed's VP Scientific Affairs, responsible for coordinating
MeMed's strategic activities with governments.

Dr. Kfir Oved, MeMed's co-founder and CTO, who has lead
development of the point-of-care platform noted: "The versatility of
MeMed's point-of-care platform derives from the similarity between
its core chemistry and that of large automated immunoassay machines.
This makes it readily amenable to transition of other protein-based
tests or signatures, ensuring cost-effective menu expandability,
which increases its potential value to the Department of Defense and
other partners."

About MeMed

Our mission is to translate the complex signals of our immune
system into simple diagnostic insights that transform the way we
treat infectious and inflammatory diseases - at the right place and
the right time. Over nearly a decade, with collaborators around the
globe, MeMed has developed and validated an immune-based protein
signature called MeMed BV(TM) for distinguishing between bacterial
and viral infections - an indispensable tool in the fight against
resistant strains of bacteria - one of the biggest healthcare
challenges of our time. An ELISA format of MeMed BV(TM), called
ImmunoXpert(TM), is cleared for use in the EU (CE-IVD), Switzerland
and Israel and is currently in pilot distribution in these
territories. MeMed is also developing MeMed Key(TM), a platform that
opens the way to measuring multiple proteins and signatures,
conventional and innovative, with central lab precision at the
point-of-need. MeMed Key(TM) measures MeMed BV(TM) within minutes.
Today, we are expanding our network of partnerships with
internationally renowned academic, commercial and government
stakeholders to advance, validate and facilitate global availability
of our platform and tests.

For additional information, please visit http://www.me-med.com.

About the Defense Threat Reduction Agency

DTRA is a Combat Support Agency and a Defense Agency with a
three-pronged mission: 1.) to counter the threats posed by the full
spectrum of weapons of mass destruction (WMD), including chemical,
biological, radiological, nuclear, and high-yield explosives; 2.)
counter the threats posed by the growing, evolving categories of
improvised threats, including improvised explosive devices, car bombs
and weaponized consumer drones, as well as the tactics, technologies
and networks that put them on the battlefield; 3.) ensure the U.S.
military maintains a safe, secure, effective and credible nuclear
weapons deterrent.

For more information visit http://www.dtra.mil

Company Contact:

Tanya Gottlieb

VP Scientific Affairs, MeMed

Phone: +972-4-8500302

tanya.gottlieb@me-med.com

ots Originaltext: MeMed Ltd
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: MeMed Ltd, übermittelt durch news aktuell